Asses Immunosuppression Modulation on Renal Recovery Post LT Not Yet Recruiting Phase 4 Trials for Everolimus (DB01590)

IndicationStatusPhase
DBCOND0122947 (Asses Immunosuppression Modulation on Renal Recovery Post LT)Not Yet Recruiting4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04104438Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver TransplantTreatment